Symphogen CEO has "no comments" on IPO plans: Will inform soon
CEO in Symphogen, Martin Olin, does not want to reveal whether the company is approaching the stock market after several changes in the managing board. He says the company will provide more information soon.
As Danish drug group Symphogen is moving closer to a potential decision of going public, the company's managing board has been subject to change with prominent names leaving as well as joining.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
